301212 Stock Overview
Zhejiang Realsun Chemical Co.,Ltd. manufactures pharmaceutical intermediates and other chemical products in China, the United States, Europe, Africa, the Middle East, Southeast Asia, and other regions.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 1/6 |
Financial Health | 6/6 |
Dividends | 2/6 |
Zhejiang Realsun Chemical Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥21.59 |
52 Week High | CN¥36.88 |
52 Week Low | CN¥13.98 |
Beta | 0.33 |
1 Month Change | 1.94% |
3 Month Change | 9.15% |
1 Year Change | -38.84% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -44.34% |
Recent News & Updates
Shareholder Returns
301212 | CN Chemicals | CN Market | |
---|---|---|---|
7D | 7.9% | 4.8% | 4.2% |
1Y | -38.8% | -18.0% | -13.2% |
Return vs Industry: 301212 underperformed the CN Chemicals industry which returned -18% over the past year.
Return vs Market: 301212 underperformed the CN Market which returned -13.2% over the past year.
Price Volatility
301212 volatility | |
---|---|
301212 Average Weekly Movement | 12.6% |
Chemicals Industry Average Movement | 8.7% |
Market Average Movement | 8.7% |
10% most volatile stocks in CN Market | 12.6% |
10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 301212's share price has been volatile over the past 3 months.
Volatility Over Time: 301212's weekly volatility has increased from 7% to 13% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 411 | Kuai Yu | www.realsunchem.com |
Zhejiang Realsun Chemical Co.,Ltd. manufactures pharmaceutical intermediates and other chemical products in China, the United States, Europe, Africa, the Middle East, Southeast Asia, and other regions. It also engages in research and development, production and sales of ABL, E2, CPMK, GBL, HDO, and IPA, as well as the trades in chemical products.
Zhejiang Realsun Chemical Co.,Ltd. Fundamentals Summary
301212 fundamental statistics | |
---|---|
Market cap | CN¥2.33b |
Earnings (TTM) | CN¥45.32m |
Revenue (TTM) | CN¥563.21m |
51.5x
P/E Ratio4.1x
P/S RatioIs 301212 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
301212 income statement (TTM) | |
---|---|
Revenue | CN¥563.21m |
Cost of Revenue | CN¥476.36m |
Gross Profit | CN¥86.86m |
Other Expenses | CN¥41.54m |
Earnings | CN¥45.32m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.42 |
Gross Margin | 15.42% |
Net Profit Margin | 8.05% |
Debt/Equity Ratio | 0.1% |
How did 301212 perform over the long term?
See historical performance and comparison